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Prostate cancer (PCa) is a very heterogeneous disease with respect to clinical outcome.
This study explored differential DNA methylation in a priori selected genes to diagnose PCa
and predict clinical failure (CF) in high-risk patients.
Methods
A quantitative multiplex, methylation-specific PCR assay was developed to assess pro-
moter methylation of the APC, CCND2,GSTP1, PTGS2 and RARB genes in formalin-fixed,
paraffin-embedded tissue samples from 42 patients with benign prostatic hyperplasia and
radical prostatectomy specimens of patients with high-risk PCa, encompassing training and
validation cohorts of 147 and 71 patients, respectively. Log-rank tests, univariate and multi-
variate Cox models were used to investigate the prognostic value of the DNA methylation.
Results
Hypermethylation of APC, CCND2,GSTP1, PTGS2 and RARB was highly cancer-specific.
However, onlyGSTP1methylation was significantly associated with CF in both independent
high-risk PCa cohorts. Importantly, trichotomization into low, moderate and high GSTP1
methylation level subgroups was highly predictive for CF. Patients with either a low or high
GSTP1methylation level, as compared to the moderate methylation groups, were at a
higher risk for CF in both the training (Hazard ratio [HR], 3.65; 95% CI, 1.65 to 8.07) and
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validation sets (HR, 4.27; 95% CI, 1.03 to 17.72) as well as in the combined cohort (HR,
2.74; 95% CI, 1.42 to 5.27) in multivariate analysis.
Conclusions
Classification of primary high-risk tumors into three subtypes based on DNA methylation
can be combined with clinico-pathological parameters for a more informative risk-stratifica-
tion of these PCa patients.
Introduction
Over the past two decades, the widespread implementation of serum prostate-specific antigen
(PSA) testing has led to a dramatic increase in the diagnosis of prostate cancer (PCa) [1]. How-
ever, many of the PSA-diagnosed tumors are clinically irrelevant. Only about a quarter of the
patients with newly diagnosed PCa are considered to be at high risk of developing fatal disease,
manifested by Clinical Failure (CF) and cancer-related death (CRD) [2–4]. According to the
European Association of Urology (EAU) and the National Comprehensive Cancer Network
(NCCN) guidelines, these high-risk PCa patients are defined by clinical stageT3a, a biopsy
Gleason score of 8–10 and/or a serum PSA level>20 ng/ml [5,6]. Nevertheless, 62–84% of the
high-risk PCa patients experience cancer-specific survival of at least 15 years after radical pros-
tatectomy (RP), demonstrating that not all patients in this group have a poor prognosis [7].
This heterogeneous clinical outcome within the high-risk group is potentially explained by the
use of risk stratification models that do not take into account underlying (epi)genetic and
molecular characteristics of the tumor which determine the presence of micrometastases.
Therefore, one of the main challenges in contemporary PCa research is to identify biomarkers
that improve the prediction of CF and CRD. A better characterization of patients with high-
risk PCa at the molecular level should allow a more personalized medicine, matching treatment
intensity to disease aggressiveness and expected prognosis. However, to date there is no estab-
lished clinical indication for using molecular prediction tools.
It is now well recognized that both mutations and epigenetic alterations, in particular differ-
ential DNA methylation, play a role in carcinogenesis [8]. DNA methylation, which occurs
mainly on cytosine residues in a sequence context of CpG dinucleotides, takes place at different
regions in the genome, i.e. at promoter CpG islands (promoter-associated CpG-dense regions),
promoter CpG island shores (region with lower CpG density in close proximity of CpG island),
gene bodies and repetitive sequences [9]. In the adult human genome most CpGs are methyl-
ated, with the exception of the promoter CpG islands and shores. It is generally accepted that
PCa is associated with alteration of these patterns, encompassing genome-wide hypomethyla-
tion as well as promoter-specific hypermethylation [8–12]. A global hypomethylation is
detected at many genomic loci, including repetitive elements and gene bodies, contributing to
genome instability and spurious transcriptional initiations, respectively. Promoter-associated
hypermethylation is associated with gene silencing and promotes PCa progression by the
silencing of tumor-suppressor genes [8,13]. In PCa, various hypermethylated genes have been
identified, with GSTP1 being the most frequently altered and studied [13].
With the present study, we aimed to develop a reliable quantitative assay to simultaneously
determine the promoter methylation levels of the a priori selected PCa-linked genes APC,
CCND2, GSTP1, RARB and PTGS2, and to evaluate their diagnostic and prognostic value for
high-risk PCa patients [13].
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Materials and Methods
Patients and sample collection
Patients with high-risk PCa were selected according to the criteria adopted by the EAU and
NCCN, i.e. a clinical stageT3a, a biopsy Gleason score of 8–10 and/or PSA levels >20 ng/
ml [5,6]. Formalin-fixed, paraffin-embedded (FFPE) normal prostate and PCa tissues were
obtained from the University Hospitals Leuven (UHL, Leuven, Belgium) and the University
Hospital of Würzburg (UHW, Würzburg, Germany). At the UHL samples were obtained
from patients with benign prostatic hyperplasia (BPH, n = 42) or high-risk PCa (PCa2,
n = 71). Samples from high-risk PCa patients were also obtained from UHW (PCa1, n = 147).
Preoperative staging in both cohorts included a digital rectal examination, an abdominopel-
vic-computed tomography (CT) scan and a bone scan. Neoadjuvant hormonal, radiation or
chemotherapy treatment were an exclusion criterion. Staging and grading of prostate cancer
samples (whole mount sections, 4 mm intervals) were performed according to the 2002 TNM
classification and the Gleason grading system, as previously described [14]. Follow-up was
performed every 3 months for the first 2 years after surgery, every 6 months in the following 3
years, and annually thereafter. CF was declared when either local recurrence or distant metas-
tases were histologically proven or confirmed by CT or bone scan. The clinico-pathological
characteristics of all cohorts are described in Table 1. Of the patients of PCa1 and PCa2
cohorts, 84% and 21%, respectively, received adjuvant treatments (radiotherapy and/or hor-
monal therapy). The study was approved by the Medical Ethics Commission of University
Hospital Leuven. The latter granted permission to perform this retrospective study without
informed consent because only archived PCa samples (left-over FFPE blocks) were used. All
samples were analyzed anonymously.
Cell culture
Human prostate PC-3 (CRL-1435, American Type Culture Collection (ATCC), Rockville, MD,
USA), LNCaP (ATCC, CRL-1740) and DU 145 (ATCC, HTB-81) cells were cultured as mono-
layers in 50% Dulbecco’s modified Eagle’s medium (DMEM) and 50% Ham’s F12, RPMI1640
and DMEM, respectively, supplemented with 10% fetal calf serum. PZ-HPV-7 cells (ATCC,
CRL-2221), an immortalized cell line derived from normal human prostate cells, were cultured
in keratinocyte-serum free medium supplemented with 5 ng/ml human recombinant epider-
mal growth factor and 0.05 mg/ml bovine pituitary extract. The benign prostatic Hyperplasia
BPH-1 cells were kindly provided by Prof. J. Swinnen (KU Leuven, Belgium) and were main-
tained in RPMI medium 1640 plus 10% fetal calf serum [15].
DNA extraction and bisulfite conversion
Whole blood human genomic DNA was purchased from Clontech Laboratories, Inc, Mountain
View, CA, USA. From cell lines genomic DNA was extracted using the GenElute Mammalian
Genomic DNA Purification Kit (Sigma-Aldrich, St. Louis, MO, USA). In the BPH cohort,
genomic DNA was extracted from the whole paraffin section, using the WaxFreeTM DNA kit
(TrimGen, Sparks, MD, USA). For both PCa cohorts, the FFPE block with the largest tumor
area was retrieved, and areas with>90% cancerous tissue, comprising both tumor epithelial
and tumor-associated stromal cells, were marked by the same uro-pathologist and subse-
quently macrodissected. Isolation of genomic DNA was performed following a standard phe-
nol-chlorophorm procedure. Next, genomic DNA (~500 ng) from each sample was bisulfite-
converted using the EZ DNAmethylation kit (Zymo Research Corp., Orange, CA, USA)
according to the manufacturer's protocol, and eluted in 25 μl H2O.
GSTP1Methylation Predicts Prostate Cancer Outcome
PLOSONE | DOI:10.1371/journal.pone.0130651 June 18, 2015 3 / 22
Methylation-independent (MI) PCR and cloning
MI primers containing maximally one CpG site close to the 5’ end were designed to amplify
100–200 base-pair (bp) fragments around the transcription start site of APC, CCND2, GSTP1,
PTGS2 and RARB (Table A in S1 File, Figure A in S1 File). MI-PCR was performed as previ-
ously described [16]. Subsequently, amplified fragments were cloned in DH5α competent cells
(Invitrogen Ltd, Paisley, UK), using the pGEM-T Easy Vector System (Promega Corporation,
Madison, WI, USA) and about 4 colonies were randomly chosen and analyzed by dideoxynu-
cleotide sequencing. Plasmids with the DNA inserts corresponding to fully methylated (derived
from LNCaP or PC-3 cells) or unmethylated (derived from human whole blood) promoter
regions after bisulfite conversion, denoted as plasmids pM and pU, respectively, were selected
for further use in the second step of the quantitative multiplex methylation-specific PCR
(QM-MSP) assay [16].
QM-MSP assay
A QM-MSP assay was developed to quantify the promoter methylation state of APC, CCND2,
GSTP1, PTGS2 and RARB (Figure A in S1 File). A detailed protocol is described in [15], and all
primer sets are defined in Table A in S1 File. Briefly, in the first PCR reaction a mixture of
Table 1. Clinico-pathological characteristics of the cohorts.
Clinical variable PCa1 cohort PCa2 cohort
Country of origin Germany (UHW) Belgium (UHL)
Number of patients 147 71
Median age* (range), y 65 (43–81) 66 (46–76)
Median preoperative PSA, ng/ml, (range) 38.30 (3.00–597.00) 19.90 (2.70–141.00)
Surgical margins, n (%)
Positive 91 (62) 28 (39)
N.A 8 (5) 0 (0)
Pathological T stage, n (%)
pT2 13 (9) 19 (27)
pT3a 35 (24) 29 (41)
pT3b 52 (35) 19 (27)
pT4 38 (26) 3 (4)
N.A. 9 (6) 1 (1)
Lymph nodes, n (%)
Positive 56 (41) 8 (11)
N.A. 10 (7) 0 (0)
Gleason score, n (%)
2–6 56 (38) 21 (30)
7 42 (28) 33 (46)
8–10 48 (33) 17 (24)
N.A. 1 (1) 0 (0)
Number of CF (%) 30 (20) 13 (18)
Median follow-up (range), y 6.85 (0.08–12.83) 11.50 (1.42–18.83)
*Median age of the patients with benign prostatic hyperplasia (n = 42) were 71 years (range, 48 to 94
years); CF, clinical failure; N.A., not available; PCa1 and 2, cohorts 1 and 2 of patients with high-risk
prostate cancer; PSA, prostate-speciﬁc antigen; y, year; UHL, University Hospital Leuven and UHW,
University Hospital Würzburg.
doi:10.1371/journal.pone.0130651.t001
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validated gene-specific primers was used to co-amplify promoters of the GSTP1, CCND2,
RARB, PTGS2 and APC genes independent of their methylation status (MI primer sets in
Table A in S1 File). To ensure that the QM-MSP can be used with highly fragmented DNA,
which is often problematic in DNA isolated from FFPE tissue, the multiplex primers were
designed to amplify PCR fragments of 100–200 bp. In the second PCR reaction, the absolute
quantification of methylated and unmethylated DNA fragments was separately performed for
each gene with the validated quantitative methylated and unmethylated specific primers (MSP
and USP primers sets, respectively, in Table A in S1 File, Figure B in S1 File). Finally, to calcu-
late the % of DNA methylation the amount of total DNA was derived from the sum of methyl-
ated and unmethylated DNA (U+M). Only samples that contain> 3000 gene copies after pre-
amplification were accepted for quantification as described in [16]. The methylation of GSTP1,
APC and CCND2 was quantified in 147 and 70 samples from the PCa1 and PCa2 cohorts,
respectively. PTGS2 was quantified in 147 and 66 samples and RARB in 146 and 66 samples
from the PCa1 and PCa2 cohorts, respectively.
Immunohistochemistry
FFPE sections of cohort PCa2 were stained on a BONDMAX autostainer (Leica). Briefly, par-
affin-embedded sections were first dewaxed, and antigen retrieval was performed in BOND
epitope-retrieval solution 1 (Leica). Mouse monoclonal 3F2 anti-GSTP1 (1:2000, 3369) and
rabbit monoclonal anti-ERG (1:100, ab92513) were purchased from Cell Signaling Technology
(Danvers, MA) and Abcam (Cambridge, UK), respectively. Slides were analyzed by light
microscopy, reviewed and scored by an uropathologist, according the Allred method [17]. The
Allred score is a semi-quantitative system that takes into account the proportion of positive
cells (scale of 0–5) and staining intensity (scale of 0–3). The proportion and intensity score
were summed to obtain the total scores of 0, 2–8. A score of 0–2 was considered as negative,
whereas 3–8 was taken as positive [17].
Statistical analysis
The BPH cohort was used to determine baseline methylation levels for all DNA methylation
markers. The receiver-operating-characteristics (ROC) analysis, sensitivity, specificity, and
positive/negative predictive value were determined using MedCalc for Windows, version 12.5
(MedCalc Software, Ostend, Belgium). The association between methylation (as continuous
variable) and clinico-pathological parameters (Gleason score and pathological stage), ERG and
GSTP1 immunostainings and stroma content was explored using the Mann-Whitney U-test
(for two categories) or Kruskal-Wallis test (for more than two categories). Fisher exact test is
used for the association between two categorical variables. Correlations between methylation
of different genes were estimated by Pearson’s correlation coefficient (r).
Categorization of DNA methylation for risk-classification was based on Cox models. The
functional relationship between the extent of DNAmethylation and time-to-event outcomes
(CF) was explored by comparing a linear trend to quadratic and cubic-splines based functions
using the likelihood ratio test [18]. One or two cut-off values were determined in case of non-
linearity. The first cut-off value was determined by considering all possible dichotomizations,
whereas the second one was determined by fixing the first cut-off and considering all possible
trichotomizations. Both model fit (likelihood) and clinical outcome per data set were consid-
ered in the final selection of these cut-off values.
The difference in risk between methylation groups was analyzed by univariate Cox models
and the log-rank test. Results are presented by means of hazard ratio (HR) and their 95% confi-
dence intervals (CI), and with a graphical representation provided by plotting the Kaplan-
GSTP1Methylation Predicts Prostate Cancer Outcome
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Meier estimates. Multivariate Cox analyses were used to design clinico-pathological models
with and without the methylation markers. The predictive accuracy of both models was evalu-
ated by means of the Concordance Probability Estimate (CPE), an AUC-like index for time-to-
event data, with values between 0.5 (no predictive value) and 1 (perfect predictive value) [19].
To ensure that the measured CPE is reproducible on out-of-sample patients, repeated random
sub-sampling cross-validation was used. The categorization of DNA methylation described
above and the weights of a Cox model were tuned on the training sets and evaluated on the cor-
responding test sets. We performed 200 random splits of the cohort into 80% training set and
20% test set. Analyses were performed using SAS software, version 9.2 for Windows (SAS Insti-
tute Inc., Cary, NC, USA). P-values<0.05 were considered statistically significant.
Results
Methylation of the five marker genes in human prostate cell lines and
whole blood
Gene-specific primer pairs were designed to amplify the CpG islands in the promoter region of
GSTP1, APC, RARB, CCND2, and PTGS2, independent of their methylation status (Table A in
S1 File). Amplification of these loci was performed in sodium-bisulphite converted genomic
DNA isolated from 5 human prostate cell lines, including three PCa (LNCaP, PC-3 and DU
145) and two benign (PZ-HPV-7 and BPH-1) cell lines, and in genomic DNA isolated from
human whole blood from a cancer-free person. DNA bisulfite sequencing of these cloned frag-
ments showed that nearly all CpG dinucleotides were methylated in LNCaP and/or PC-3 can-
cer cell lines, but not in benign cell lines and blood (illustrated in Figure A in S1 File for APC).
Next, QM-MSP for the five selected genes was developed as described in the materials and
methods section and performed in these six genotypes (Table 2). All genes were completely
methylated (99% methylation) in the hormone-sensitive LNCaP cells, in accordance with
our bisulphite sequencing data and previous studies [20]. In the hormone-refractory cell lines
PC-3 and DU 145, the DNAmethylation levels were less prominent, as only two genes (APC
and PTGS2) were 100% methylated in PC-3 line, while none of the genes was completely meth-
ylated in the DU 145 cells. DNA methylation in the non-malignant genotypes, including BPH-
1, PZ-HPV7 and whole blood, was not detected at the GSTP1, RARB, PTGS2, CCND2, and
APC gene loci, except for CCND2 in BPH-1, which was 13% methylated.
Cancer-specific DNA methylation in high-risk PCa
Next, the promoter methylation of APC, CCND2, GSTP1, PTGS2 and RARB was quantified in
FFPE prostate tissue samples, using the QM-MSP procedure. Samples were derived from the
Table 2. DNAmethylation of the five marker genes in human prostate cell lines and whole blood.
Human prostate cell lines
Cancer Benign
Genes LNCaP PC-3 DU 145 BPH-1 PZ-HPV HWB*
GSTP1 100 32 7 0 0 0
APC 100 100 0 0 0 0
RARB 100 0 0 0 0 0
PTGS2 100 100 61 0 0 0
CCND2 99 30 90 13 0 0
*HWB, genomic DNA was isolated from human whole blood from a cancer-free person.
doi:10.1371/journal.pone.0130651.t002
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transurethral resection or adenomectomy specimens of 42 patients with BPH and the radical
prostatectomy specimens of 218 patients with high-risk PCa. The PCa patients comprised two
groups, further denoted as the PCa1 or training cohort (n = 147) and PCa2 or validation
(n = 71) cohort. In the BPH cohort, the average methylation level of these marker genes did
not exceed 2% (Fig 1, Table B in S1 File). However, a much higher degree of CpG methylation
was detected for all genes in both high-risk PCa cohorts, indicating a cancer-specific methyla-
tion of the selected markers (Fig 1, Table C and D in S1 File). With a methylation cutoff value
of 1 or 2%, GSTP1 showed the highest sensitivity in PCa1 (0.99) and PCa2 (0.97) cohorts, at a
specificity of 1.00 for the five single markers (Table E in S1 File). Other combinations of
marker genes did not further improve the sensitivity without decreasing the specificity
(Table E in S1 File). To further assess the accuracy in discriminating high-risk PCa from BPH,
receiver-operating-characteristics (ROC) analysis for each of the single markers was per-
formed and the area under the curve (AUC) was calculated (Fig 1). The AUCs ranged from
0.85 (PTGS2) to 0.99 (GSTP1), confirming cancer-specific methylation, with GSTP1methyla-
tion as the best classifier.
Methylation heterogeneity in high-risk PCa
The methylation level of all single genes varied from 0% to ~80%, suggesting a huge inter and
intratumor molecular heterogeneity in high-risk prostate tumors (Fig 1). Since the DNA was
extracted from areas with>90% cancerous tissue, comprising both tumor-epithelial and
tumor-associated stromal cells, we have semi-quantified the stroma content of the tissues from
the PCa2 cohort and analysed the correlation with GSTP1 DNAmethylation. The stroma con-
tent varied from 10% to 35% with two outliers of 40 and 60% (Table F in S1 File). Importantly,
no correlation was found between GSTP1 DNAmethylation and stroma content, as analysed
by Spearman (P-value, 0.1550), Kruskal-Wallis and Fisher exact tests (Table G in S1 File), indi-
cating that the difference in stroma content is not the underlying cause for inter and intratu-
mor heterogeneity of the DNA methylation. Therefore, our data are consistent with the notion
that there is a large inter and intratumor heterogeneity in high-risk PCa at the DNA methyla-
tion level.
Interestingly, by ranking the patients of the training and validation cohorts according to the
methylation level of GSTP1, the most frequently methylated marker gene, we found that the
methylation level of the other 4 markers generally followed the same pattern in both cohorts
(Fig 2A). In addition, scatter plot analyses between methylation of GSTP1 and the other genes
(Fig 2B and Figure C in S1 File) revealed that tumors that were not methylated at APC,
CCND2, PTGS2 or RARB, were often methylated at GSTP1, with levels ranging from ~5 to
70%. However, if the tumors were hypermethylated at APC, CCND2, PTGS2 or RARB, their
methylation degree was generally proportional to the GSTP1methylation levels. These findings
were corroborated by the highly significant positive Pearson correlation coefficients of the
methylation levels of these markers (r = 0.45–0.82; P< 0.001; Table H in S1 File). Taken
together, these data show that the methylation of the five genes is moderately to strongly corre-
lated and most likely occurs in the same cells.
Promoter hypermethylation versus clinico-pathological parameters
Correlations between the methylation of the gene loci, the pathological stage (pT), and the
Gleason score (GS) were evaluated in both PCa cohorts. None of the markers showed a signifi-
cant association with pT, which was categorized into four groups (pT2, pT3a, pT3b and pT4).
For GS, the data were separated into groups of low (GS2-6), intermediate (GS7) and high grade
(GS8-10). The median methylation levels for these groups are given in Table 3. Based upon the
GSTP1Methylation Predicts Prostate Cancer Outcome
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Fig 1. Comparison of DNA-marker methylation in benign prostatic hyperplasia (BPH) and high-risk
PCa. The methylation of RARB,GSTP1, APC, CCND2 and PTGS2 was determined by QM-MSP in radical
prostatectomy samples from 42 patients with BPH and from 147 (PCa1) and 71 (PCa2) patients with high-risk
PCa. The data are shown in dot plots for the indicated genes (A-E, left graphs). Methylation levels of every
gene in each PCa cohort were significantly higher than in the BPH group, as determined by the Mann-
GSTP1Methylation Predicts Prostate Cancer Outcome
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Kruskal-Wallis and Mann-Whitney U tests, none of the markers were significantly associated
with the GS in both cohorts (Table 3 and Tabel I in S1 File). Pairwise comparisons of the GS
groups revealed that only PTGS2methylation was significantly increased in GS8-10 and GS7,
as compared with GS2-6, in PCa1 (Table I in S1 File). APC and RARBmethylations were only
significantly higher in GS7, as compared with GS2-6, in PCa2 (Table I in S1 File).
Whitney U-test (*, P<0.001). Receiver-operating-characteristic (ROC) analysis the methylation markers to
discern BHP from high-risk prostate cancer samples (A-E; middle, PCa1 and right, PCa2), using the data
displayed in the dot plots was performed. Grey line, median; AUC, area under the curve.
doi:10.1371/journal.pone.0130651.g001
Fig 2. Range of DNAmarker methylation in patients with high-risk PCa.Color-scaled representation of DNAmethylation in tumors from the PCa1 and
PCa2 cohorts. (A) The patients were ordered according to theirGSTP1methylation value. The% of methylation of the other 4 marker genes is also shown.
Grey boxes indicate missing values. (B) Scatter plots of the correlation betweenGSTP1methylation and RARBmethylation in PCa1 (left panel) and PCa2
(right panel) cohorts.
doi:10.1371/journal.pone.0130651.g002
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GSTP1methylation predicts clinical failure in high-risk PCa patients
Next, we have explored the relationship between the extent of marker methylation and clinical
failure, using Cox models [21]. Clinical failure was declared when either local recurrence or dis-
tant metastases were histologically proven or confirmed by CT or bone scan. No significant lin-
ear relationship was found between each of the five genes and CF. Since it is well established
that biomarkers, when applied clinically, are often dichotomized, we used cox models for
selecting the optimal cutoffs for each of the single markers [22]. Univariate and multivariate
cox regression analysis revealed that dichotomization based on CCND2, GSTP1, PTGS2, or
RARBmethylation was only significantly correlated with CF in one cohort, indicating that it is
clinically irrelevant (Table J in S1 File). Nevertheless, we noticed that GSTP1methylation was
significant associated with CF in PCa1 and PCa2 when different cutoffs were used, i.e, 15% and
50%, respectively (Table J in S1 File). Therefore, we investigated the clinical outcome of multi-
ple GSTP1methylation subgroups. The high-risk tumors were categorized into three groups,
based upon the GSTP1methylation level, i.e. low methylation (LM, methylation<15%), mod-
erate methylation (MM, methylation 15–50%) and high methylation (HM, methylation
>50%). Patients with either low or high methylation, as compared to the moderate methylation
groups, were at a significantly higher risk for CF in the training PCa1 cohort, as shown by uni-
variate Cox regression analysis (Table 4; HR, 2.96; 95% Cl, 1.38–6.36; P-value 0.005). This
increased risk was validated in the PCa2 cohort (Table 4; HR, 3.34; 95% Cl, 1.03–10.89; P-value
0.045) as well as the combined cohort (Table 4; HR, 2.59; 95% Cl, 1.38–4.87; P-value 0.003). In
addition, univariate Cox regression analysis of preoperative PSA, GS and pT revealed that only
GS was a significant predictor for clinical failure in both cohorts (Table 4). The prognostic
power of GS in these cohorts is in agreement with several previous studies [14,23,24].
To further support the notion that trichotomization of high-risk PCa patients based on
their GSTP1methylation level improves prediction of clinical outcome, survival probabilities
for each group were displayed using Kaplan-Meier plots (Fig 3). This analysis revealed a signifi-
cant separation in the curves in both the training (log-rank test, P-value 0.014) and validation
(log-rank test, P-value 0.043) cohorts as well as in the combined cohort (log-rank test, P-value
0.006) (Fig 3A, 3C and 3E). A comparison of the LM + HM and the MM groups revealed that
more than half of the high-risk PCa patients were classified in the MM subgroup and had a
much better CF-free survival in PCa1 (log-rank test, P-value 0.007) and the combined group
Table 3. Correlation analysis of DNAmethylation and Gleason score.
GSTP1 APC RARB PTGS2 CCND2
Cohort Gleason score n M % (Q1–Q3) n M % (Q1–Q3) n M % (Q1–Q3) n M % (Q1–Q3) n M % (Q1–Q3)
PCa1 2–6 56 41 (20–53) 56 25 (6–49) 56 27 (12–47) 56 6 (0–26) 56 10 (3–24)
7 42 42 (29–52) 42 41 (12–53) 41 34 (20–49) 42 19 (6–45) 42 12 (6–28)
8–10 48 39 (30–52) 48 41 (21–52) 47 35 (19–54) 48 27 (7–39) 48 17 (5–29)
P Value* 0.604 0.135 0.165 0.007 0.402
PCa2 2–6 21 20 (12–30) 21 16 (1–27) 20 8 (0–24) 18 2 (1–10) 21 4 (1–7)
7 32 26 (15–39) 32 25 (12–39) 30 24 (12–37) 32 12 (1–21) 32 6 (3–11)
8–10 17 15 (7–43) 17 23 (13–34) 16 16 (7–30) 16 7 (1–11) 17 1 (1–5)
P Value* 0.335 0.134 0.082 0.145 0.060
Pathological stage was tested without showing signiﬁcant correlations to hypermethylation. n, number of patients; M = Median DNA methylation (%), Q1,
percentile 25; Q3, percentile 75;
*, Kruskal-Wallis test.
doi:10.1371/journal.pone.0130651.t003
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(log-rank test, P-value 0.002). However, this difference was borderline in the PCa2 cohort (log-
rank test, P-value 0.062).
Importantly, the trichotomized GSTP1methylation emerged as an independent predictor of
CF when adjusted for pT, final GS, pre-operative PSA level in both the training (Table 4; HR,
3.65; 95% CI, 1.65–8.07; P-value 0.001) and validation cohorts (Table 4, HR, 4.27; 95% CI,
1.03–17.72; P-value 0.046), as well as in the joint cohort (Table 4; HR, 2.74; 95% CI, 1.42–5.27;
P-value 0.003). Among the other tested variables, only the GS also emerged as an independent
predictor of CF in both the single and combined cohorts. Thus, DNAmethylation has predic-
tive power independent of GS in high-risk PCa.
Next, we compared the predictive value of the model for CF, including all clinico-pathologi-
cal parameters, with and without trichotomized GSTP1methylation, by means of Concordance
Probability Estimates (CPEs) [19]. The performance measures were significantly improved by
the inclusion of GSTP1methylation in the clinical model in both cohorts (Table 5). Thus, the
accuracy of the predictive models for CF based on clinico-pathological parameters can be fur-
ther improved by inclusion of the trichotomized GSTP1methylation model.
Methylation-guided risk-stratification of patients with high-risk PCa
Since the survival analyses showed that patients with either low or high levels of GSTP1meth-
ylation are at a higher risk for CF than those with moderate GSTP1methylation levels, we
explored the methylation level of the other 4 tested markers in these subgroups. First, we strati-
fied the patients of the training, validation and combined cohorts into three groups, i.e. low
(<15%), moderate (15%-50%) and high (>50%) methylation, by ranking them according to
the GSTP1methylation level (Fig 4A). When the data of all five marker genes were combined,
the median methylation values in the LM groups did not exceed 6% and, except for a few
Table 4. Univariate andmultivariate Cox regression analysis of clinical failure in high-risk prostate cancer.
Univariate Multivariate
Variable HR 95% CI P-value HR 95% CI P-value
Training Cohort (PCa1)
GSTP1 trichotomized: MM vs LM+HM 2.96 1.38–6.36 0.005 3.65 1.65–8.07 0.001
Pathological T stage 2-3a vs 3b - 4 2.28 0.93–5.61 0.072 1.69 0.67–4.26 0.268
Gleason score 2–7 vs 8–10 3.40 1.63–7.09 0.001 4.82 2.18–10.66 < 0.001
Preoperative PSA continuous 1.00 1.00–1.01 0.640 1.00 0.99–1.01 0.716
Validation Cohort (PCa2)
GSTP1 trichotomized: MM vs LM+HM 3.34 1.03–10.89 0.045 4.27 1.03–17.72 0.046
Pathological T stage 2-3a vs 3b - 4 7.03 2.14–23.09 0.001 7.15 2.08–24.61 0.002
Gleason score 2–7 vs 8–10 7.49 2.28–24.68 < 0.001 7.12 1.83–27.80 0.005
Preoperative PSA continuous 1.01 1.00–1.03 0.107 1.02 1.00–1.04 0.106
Combined cohort (PCa1 and 2)
GSTP1 trichotomized: MM vs LM+HM d 2.59 1.38–4.87 0.003 2.74 1.42–5.27 0.003
Pathological T stage 2-3a vs 3b-4 3.99 1.93–8.24 < 0.001 3.82 1.75–8.36 < 0.001
Gleason score 2–7 vs 8–10 4.56 2.43–8.55 < 0.001 4.35 2.28–8.28 < 0.001
Preoperative PSA continuous 1.00 1.00–1.01 0.129 1.00 1.00–1.01 0.388
Hazard Ratio (HR) >1 (<1) indicates higher (lower) risk for the second group. GSTP1, % GSTP1 methylation; CF, clinical failure; CI, conﬁdence interval;
HM, high methylation; LM, low methylation; MM, moderate methylation; PCa1 and 2, cohorts 1 (n = 147) and 2 (n = 71) of patients with high-risk prostate
cancer; PCa1+2, a combined group of patients from PCa1 and PCa2.
doi:10.1371/journal.pone.0130651.t004
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Fig 3. Kaplan-Meier survival plots for patient methylation subgroups. The curves show CF-free survival of patients from the low (LM, <15%GSTP1
methylation), moderate (MM, 15–50%GSTP1methylation) and high (HM, >50%GSTP1methylation) groups in PCa1 (A), PCa2 (C) and PCa1+2 (E).
Comparison of CF-free survival between the MM and LM+HM groups in PCa1 (B), PCa2 (D) and in PCa1+2 (F) is also shown. CF, clinical failure; P, log-rank
test P-value. P-value, log rank test.
doi:10.1371/journal.pone.0130651.g003
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outliers, the absolute values were less than 25% in both the single and combined cohorts (Fig
4B–4D). This is consistent with the high Pearson correlation coefficients (Table H in S1 File)
and suggests that only a small percentage of the cells in LM tumors were methylated at the
marker genes. In contrast, the median methylation values for the marker genes in the MM/HM
groups reached 18/45% (training set), 28/50% (validation set) and 25/50% (combined set),
respectively. Importantly, when the patients were ranked according to the methylation state of
APC, RARB, CCND2 or PTGS2, their segregation into low, moderate and high methylation
subtypes was less manifested, as each of those markers showed a lower sensitivity, as compared
with GSTP1 (Figure D in S1 File). Collectively, these data suggest that only categorization
according to the GSTP1methylation level defines subgroups with globally low, moderate or
high methylation levels in high-risk prostate patients. Patients with either low or high DNA
methylation levels are clearly at higher risk for CF than patients with a moderate DNAmethyl-
ation level (Figure E in S1 File).
ERG and GSTP1 expression in high-risk PCa
It is well established that gene fusions, including TMPRSS2-ERG fusions with concurrent ERG
overexpression, represent the most frequent genetic alterration in PCa [25,26]. Therefore, we
have performed ERG stainings in cohort PCa2 and analyzed the association with GSTP1meth-
ylation. Positive ERG staining was found in 62% of the PCa tissues, which is consistent with
prior reported frequencies of ERG fusions (Fig 5, Table F in S1 File) [25,26]. No significant cor-
relation was found between the ERG level and GSTP1 DNAmethylation, as analysed by Krus-
kal-Wallis and Fisher exact tests (Table G in S1 File).
Next, to explore the correlation between GSTP1methylation and expression we performed
GSTP1 immunostaining on the samples of cohort PCa2. Positive GSTP1 was only found in 5
tumors, and the other 63 samples were completely negative for GSTP1 in the epithelial tumor
cells (Fig 5, Table F in S1 File). Importantly, the basal cells of normal prostate glands and the
stromal cells served as internal positive staining controls on each slide. Although hypermethy-
lation of GSTP1 gene is often associated with a loss of GSTP1 expression, we found no associa-
tion between GSTP1 staining and GSTP1 DNAmethylation (Table G in S1 File). This suggests
that the GSTP1 gene is inactivated by other mechanisms, as reported by others [27,28], or is
hypermethylated at a region that was not analyzed in our study. The five tumors that stained
positively for GSTP1 showed a mixed population of positive and negative tumor cells, clearly
Table 5. Performance of multivariate Cox regression of clinical failure in high risk prostate cancer.
Variable CPE ± CI*
Training cohort (PCa1)
Three clinical variables 0.684 ± 0.052
Three clinical variables + GSTP1 0.717 ± 0.051
P-value$ 0.003
Validation cohort (PCa2)
Three clinical variables 0.747 ± 0.099
Three clinical variables + GSTP1 0.797 ± 0.084
P-value$ 0.001
*Condiﬁdence intervals (CI) of the measures on 200 sampled test sets are reported.
$P-values were produced by paired t-tests on the 200 measures. CPE, Concordance Probability Estimate;
GSTP1, % DNA methylation of GSTP1 gene; PCa1 and 2, cohorts 1 (n = 147) and 2 (n = 71) of patients
with high-risk prostate cancer.
doi:10.1371/journal.pone.0130651.t005
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Fig 4. Methylation-guided sub-stratification of patients with high-risk PCa. (A) Color-coded representation of DNAmethylation in tumors from the
combined PCa1 + PCa2 cohort. The patients were ranked according to theirGSTP1methylation value and classified into low (LM), moderate (MM) and high
(HM) methylation subtypes, based onGSTP1methylation levels of < 15%, 15–50% and > 50%. The % of methylation of the other 4 marker genes is also
shown. Grey boxes indicate missing values. (B-D) Box-whisker plots of the methylation of the 5 marker genes in the LM, MM and HM groups of the training,
validation and combined cohorts. The boxes mark the 25th-75th percentiles, the median value (horizontal line in the boxes), and the minimal and maximal
values (whiskers). Circles indicate the “outside” values (defined as those that are larger than the upper quartile plus 1.5 times the interquartile range). A filled
triangle indicates a “far out” value (defined as that larger than the upper quartile plus 3 times the interquartile range). (*) P < 0.001, Mann-Whitney U test.
doi:10.1371/journal.pone.0130651.g004
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Fig 5. ERG and GSTP1 immunostainings of PCa samples from cohort PCa2.Representative
immunohistochemical images of PCa samples are shown that were positive for ERG and negative for GSTP1
(A), positive for both ERG and GSTP1 (B), negative for both ERG and GSTP1(C), and negative for ERG and
positive for GSTP1 (D). The internal staining control for ERG is the endothelium (arrows) and for GSTP1 the
stromal and/or basal cells of normal prostate glands. N, normal prostate gland; S, Stroma; T, tumor gland.
Scale bars equal 100μm.
doi:10.1371/journal.pone.0130651.g005
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demonstrating intra-tumor heterogeneity at the GSTP1 level (Fig 5). Combining the GSTP1
and ERG stainings, we found that 58% of the tumors stained positive for ERG and negative for
GSTP1 (Fig 5A), 4% positive for both ERG and GSTP1 (Fig 5B), 35% negative for both ERG
and GSTP1 (Fig 5C), and 3% negative for ERG and positive for GSTP1 (Fig 5D).
Discussion
Coordinated cancer-specific methylation in PCa
Comparison of BPH and PCa samples revealed that the methylation of the 5 selected markers
is highly PCa-specific, with GSTP1 being the most frequently methylated marker. Of all ana-
lysed PCa specimens, 58% showed methylation at all five genes, and 73% at four loci, encom-
passing GSTP1 and at least three other loci. Tumors that were not methylated at APC, CCND2,
PTGS2 and/or RARB, were often methylated at GSTP1, with levels ranging from ~5 to 70%.
This agrees with GSTP1 being the most sensitive marker in our study and is consistent with
reports indicating that GSTP1 is one of the most altered and earliest epigenetic event during
PCa development [29]. We have also observed that if the tumors were hypermethylated at
APC, CCND2, PTGS2 or RARB, their methylation degree was generally proportional to the
GSTP1methylation levels, suggesting a common underlying mechanism. Accordingly, Spear-
man analyses revealed that the methylation of the five marker genes was moderately to strongly
positively correlated, in agreement with earlier studies [30,31]. Florl et al. (2004) reported a
simultaneous hypermethylation of GSTP1, RARB2, RASSF1A and APC [30]. Yegnasubrama-
nian et al. (2004) found a similar correlation for the methylation of GSTP1, APC, RASSF1A,
PTGS2 andMDR1 [31]. Coordinated methylation has also been found for RARB and TIG1 by
Zhang et al. (2004). These authors proposed that the methylation of TIG1 was a downstream
effect of the inactivation of RARB [32]. More recently, global methylation profiling has revealed
hundreds of differentially methylated DNA regions in PCa, which supports the coordinated
hypermethylation of gene sets [33–41]. For example, the 25 most hypermethylated genes in
PCa compared to normal tissue, including GSTP1 and RARB, showed sensitivities and specific-
ities between 89 and 100%, respectively, confirming the simultaneous methylation of these
markers [37]. Although the molecular mechanism underlying DNAmethylation changes in
PCa remains unclear, it has been linked to an increased expression of DNA methyltransferases
(DNMTs) and the chromatin modifier EZH2, a dysregulation of DNMT–interacting proteins,
and a reduced level of the hydroxymethylase TET1 [36,42,43]. Interestingly, GSTP1, APC and
PTGS2 are known TET1 targets [42,43].
Intriguingly, GSTP1 immunostainings revealed that ~ 90% of the tumors from the PCa2
cohort did not express GSTP1 in any of the epithelial tumor cells. Since the GSTP1 DNAmeth-
ylation levels ranged from 0–80%, these data therefore suggest that other mechanisms inacti-
vate the GSTP1 gene. Accordingly, Jeronimo et al. (2002) found that 62% of microdissected
prostate adenocarcinomas with unmethylated GSTP1 showed no GSTP1 protein expression
[27]. Accumulating evidence suggests that the GSTP1 gene can be downregulated by other
mechanisms, involving signaling by the estrogen receptor and the endothelial nitric-oxide
synthase complex as well as several miRNAs [28,44,45].
Inter and intratumor heterogeneity in DNAmethylation
Since the methylation level is a measure of the percentage of cells from the dissected area that
is differentially methylated and the methylation level of individual genes varied from 0% to
~80%, our data suggest massive inter and intratumor heterogeneity in DNA methylation of
high-risk PCa. Importantly, since the stroma content was not correlated with DNAmethyla-
tion, we can exclude that the difference in stroma content is the underlying cause of this tumor
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heterogeneity. Also, we have found that the tumors that expressed GSTP1 showed a mixed
population of positive and negative cells, hinting at intratumor heterogeneity with respect to
GSTP1 expression. Brocks et al. (2014) also reported a high intratumor heterogeneity in DNA
methylation in aggressive PCa and concluded that the epigenome variation extends the intratu-
mor heterogeneity of PCa along with genetic variation [46].
About 20% of the high-risk patients from the combined cohort belonged to the LM subtype
(Fig 4). In this LM group, the average methylation of all five markers amounted to
7.00 ± 0.54%, which represented a significantly higher value than that of benign samples (aver-
age methylation 0.13 ± 0.01%; P value< 0.0001 (t-test)). This agrees with the high sensitivity
of the markers (Fig 1 and Table E in S1 File). We can exclude poor DNA quality as an explana-
tion for the low methylation values, because we amplified an adequate amount of DNA in all
LM samples. Since the methylation patterns of the five examined marker genes were strongly
correlated, this suggests that the LM tumors only contain a small percentage of cells with
hypermethylated genes. These LM patients could only be identified because the methylation in
our cohorts was selectively quantified in tumor tissue, which prevents ‘dilution’ of the hyper-
methylation signal by normal tissue. This suggests that PCa patients with LM tumors will prob-
ably not be identified when body fluids, including blood and urine, are used for the detection
of marker gene hypermethylation. At present it cannot be excluded that LM tumors were ini-
tially hypermethylated, but somehow lost their methylation during the later stages of tumori-
genesis. A genome-wide analysis also identified a subset of unmethylated metastatic PCa
tumors, which did not co-segregate with clinico-pathological factors [34].
Although the underlying molecular mechanism of the LM subclass remains unclear, we
hypothesize that the LM tumors represent a biologically distinct subclass of PCa at the epige-
netic and molecular level. We speculate that key enzymes for altering the methylome, including
DNMTs and/or TETs, are not affected in these tumors. Since aberrant methylation is thought
to contribute to tumorigenesis by repressing transcription of tumor suppressor genes, we spec-
ulate that other mechanisms are responsible for the inactivation of the tumor suppressor genes
in the LM tumors [20,47]. Finally, we did not find a correlation between the ERG level and
GSTP1 DNAmethylation, suggesting hat the LM tumors are not different from the MM or
HM tumors with respect to ERG rearrangements. Consistent with this view, Kim et al (2011)
found no difference in the methylation status at the GSTP1 locus in ERG-positive and negative
cancers [20]. In contrast, Borno et al. (2012) showed that gene-fusion negative tumors have sig-
nificantly more methylation alteration events, including hypermethylation ofmiR-26a, as com-
pared to the positive tumors. Kron et al. (2012) found that ERG-positive tumors were more
methylated on CYP26A1, TBX15 and HOXD3 than the ERG-negative tumors [48,49]. Further
investigations are needed to unravel the molecular basis of the LM tumors subclass.
DNAmethylation-guided risk-stratification in high-risk PCa
Currently, risk-stratification of PCa patients into low, intermediate and high-risk groups, is
exclusively based on clinico-pathological parameters, including PSA, GS and clinical stage.
However, these groups, in particular the high-risk group, have a very heterogeneous outcome
[7]. In line with these observations, we found a great inter and intratumor heterogeneity with
respect to DNAmethylation level of the selected marker genes in the high-risk patients.
Through explorative statistical analyses we found that the classification of high-risk PCa into
LM, MM and HM groups, based on their GSTP1methylation level, is significantly associated
with the prediction of clinical outcome. Indeed, statistical analysis revealed that LM tumors are
not less aggressive than HM tumors, and that the combination of both groups is a strong pre-
dictor for CF, independent of established clinico-pathological prognostic factors. In line with
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these results, the predictive value of the clinico-pathological model for CF significantly
increased after addition of GSTP1methylation to the model. Our study is the first to show a
significant association between GSTP1methylation and CF in two independent high-risk
cohorts, stressing the clinical relevance of these findings. Since both the LM and HM groups
showed a worse prognosis compared to the MM group, this enabled us to further risk-stratify
high-risk PCa patients.
Promoter hypermethylation of the GSTP1 gene is the most common epigenetic alteration in
PCa and one of the most extensively studied, in particular for PCa diagnostics [50,51]. GSTP1
methylation has been detected in over 90% of primary PCa and 70% of prostatic intraepithelial
neoplasia (PIN) lesions, but only rarely in normal prostate [50,52]. In addition, GSTP1 hyper-
methylation has been detected in urine and serum of PCa patients, and has emerged as the
most promising epigenetic diagnostic biomarker for PCa [51]. Although the diagnostic utility
of GSTP1 methylation is generally accepted, its prognostic value is unclear. Several groups
have evaluated GSTP1 methylation as a prognostic biomarker for PCa, but reported discrepant
results. Since it is essential to evaluate a prognostic marker by multivariate analyses to be clini-
cally relevant, we focus here our discussion on prognostic studies with multivariable analyses.
Ellinger et al. (2008) and Alumkal et al (2008) did not find an association between GSTP1
DNAmethylation and biochemical recurrence, while Richiardi et al. (2009) and Vasiljevic et al.
(2014) found no correlation with mortality [53–56]. In contrast, Rosenbaum et al. (2005) and
Devaney et al. (2011) found an inverse correlation between GSTP1methylation with disease
progression [33,57]. Other studies have reported an association between GSTP1methylation
and poor patient outcome [58–60]). Bastain et al. (2005) demonstrated that men with clinically
localized PCa and detectable hypermethylated GSTP1 in preoperative serum were at a signifi-
cantly higher risk for PSA recurrence than those without methylated GSTP1 [58]. In accor-
dance with these data the group of Sidransky has found an association between GSTP1
hypermethylation and disease recurrence in early stage PCa [59]. Finally, Clark and co-workers
reported that detectable plasma levels of methylated GSTP1 were associated with a poorer
response to chemotherapy in castrate-resistant PCa and a poorer survival [60]. Thus, conflict-
ing data regarding the prognostic value of GSTP1 have been reported. These are probably due
to the differences in the adopted methodologies, sample sizes, (neo)adjuvant treatments and/or
outcome measurement criteria [61]. Our data suggest that the discrepancies between these
studies may be linked to the non-linear association between GSTP1methylation and disease
progression. We hypothesize that a categorization into three GSTP1methylation level sub-
groups is required to detect the association with CF. From a clinical point of view, we believe
that it is important to determine whether DNA methylation is altered in tumors. Hypermethy-
lated GSTP1 will generally be associated with a poorer outcome, which could contribute to a
rational decision on further patient treatment. If GSTP1methylation is not altered, DNAmeth-
ylation was probably not involved in tumor development and epigenetic drugs are unlikely to
be effective.
Our study has multiple strengths. We had an extremely long clinical follow-up of 11 and 7
years in the training and validation sets, respectively. We have obtained consistent results for
both patient cohorts, despite their different countries of origin. In addition, the DNA was
extracted exclusively from tumor regions, as mapped by the same pathologist, allowing us to
study intratumor heterogeneity with respect to DNAmethylation. Nevertheless, our study is
not devoid of limitations. The groups are not homogeneous regarding the use of adjuvant and
salvage radiotherapy or androgen deprivation therapy and, due to the long study period, we
cannot exclude changes in staging, surgical techniques and/or secondary treatments. Although
the tumor samples were macro-dissected from a well-defined tumor area, they were heteroge-
neous with respect to stroma content, which may have affected the detected methylation
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profiles. In addition, CpG sites can be either methylated or unmethylated in each allele, which
may have resulted in heterogeneous DNA methylation patterns [62]. Therefore, it should be
taken into consideration that MSP-based assays examine the DNA methylation status of the
CpG sites that are only present in the primer binding sites and do not necessarily reflect the
DNAmethylation status of other CpG sites. Hence, the DNA methylation levels in tumor sam-
ples depend on the amplicon that is amplified. Despite the fact that our study deals with high-
risk cancers, the clinical failure rates were rather limited, which may have obscured the detec-
tion of modest effects. Therefore, we cannot exclude that significant methylation effects for
APC, CCND2, PTGS2 and RARB will surface in larger-scale studies. Furthermore, a larger-scale
analysis should reveal whether the quadratic relationship between GSTP1 DNAmethylation
and CF also applies to the low and intermediate risk groups.
In conclusion, our data suggest that the classification of primary high-risk PCa tumors into
DNAmethylation subtypes i.e. low, moderate and high DNAmethylation level groups, can be
combined with clinico-pathological parameters for a more informative risk-stratification.
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